Covance offers service to keep contracts under control

Covance ($CVD) has launched a managed markets service platform designed to help its biopharma and medical device clients deal with managed care organizations, group purchasing outfits, federal and state programs and wholesalers. The industry loses up to 4.4% of its annual revenue due to insufficient processes and contract management systems, Covance said, costing $11 billion a year. More

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.